Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: A critical appraisal of 48 cases

Annals of Surgery

Volumn 251, Issue 5, 2010, Pages 910-916

  Saxena, Akshat ^a   Chua, Terence C ^a   Bester, Lourens ^a   Kokandi, Adel ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FLUOROURACIL; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; MALE; NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR LIVER METASTASIS; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIOEMBOLIZATION; RADIOTHERAPY; TREATMENT RESPONSE;

AGED; ALKALINE PHOSPHATASE; CARCINOMA, NEUROENDOCRINE; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PROGNOSIS; YTTRIUM RADIOISOTOPES;

EID: 77951666352     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181d3d24a     Document Type: Article

References (34)

1. Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg. 1987;206:115-125.
2. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
3. Veenendaal LM, Borel Rinkes IH, Lips CJ, et al. Liver metastases of neuroendocrine tumors; early reduction of tumor load to improve life expectancy. World J Surg Oncol. 2006;4:35.
4. Godwin JD II. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36:560-569.
5. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metas-tases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445.
6. McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg. 1994;81:1007-1009.
7. Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(suppl 2):S3-S8.
8. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg. 1995;19:76-82.
9. Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases. Am J Surg. 2004;187:39-46.
10. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10-19.
11. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer. 1995;76:501-509.
12. Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neu-roendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005;30:435-441.
13. Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery. 1997;122: 1040-1047; discussion 1047-1048.
14. de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. Am J Roentgenol. 2000;175:1619-1625.
15. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoem-bolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J. 2003;9:261-267.
16. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293-2301.
17. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytore-duction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-581.
18. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoemboliza-tion and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188:1201-1207.
19. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17:474-478.
20. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors-a retrospective single-center analysis. Digestion. 2003;68:94-101.
21. Rhee TK, Lewandowski RJ, Liu DM, et al. Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029-1035.
22. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendo-crine tumors: variables affecting response rates and survival. Cancer. 2005; 104:1590-1602.
23. O'Toole D, Hentic O, Corcos O, et al. Chemotherapy for gastro-enteropan-creatic endocrine tumors. Neuroendocrinology. 2004;80(suppl 1):79-84.
24. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-4904.
25. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroen-teropancreatic tumors. Gut. 1996;38:430-438.
26. Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumors. Report on a double-blind, randomized trial. J Intern Med. 1995;237:269-275.
27. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachy-therapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
28. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19:951-959.
29. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unre-sectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
30. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008; 113:921-929.
31. Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol. 2007;18:1310-1314.
32. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278. (Pubitemid 44259009)
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
34. Caprotti R, Angelini C, Mussi C, et al. Gastrointestinal carcinoids. Prognosis and survival. Minerva Chir. 2003;58:523-532.